Since the introduction of randomised controlled trials, professionals and lay people alike have worried over whether doing this sort of experiment in humans is ethical. It has been argued that participants may be called to sacrifice their own best interests for the benefit of future patients.1 The scientific rationale for conducting a trial rests in collective equipoise, which means that the medical community as a whole is genuinely uncertain over which treatment is best. The key point, however, is that future patients benefit at no cost to participants, provided that participants are in personal equipoise and give informed consent on this basis. In these circumstances, the trial arms are an equally good bet prospectively.
2
MethodsTo find out what patients, the general public, and healthcare professionals thought about trials, we undertook a review of the ethics of randomised controlled trials from these perspectives as part of a broader review relating to the ethics of designing and conducting clinical trials.1 We searched BIDS, Medline, and Psychlit (for strategy see the BMJ website). There were 61 studies on attitudes to trials, 54 based on quantitative methods and eight based on qualitative ones (one study used both). Twenty studies made use of hypothetical trial scenarios. Seven studies focused on early trials (phases I and II). Our search also identified three reviews that included views on clinical trials, [3][4][5] but only one was a systematic review and even this study gave only limited information about the quality of the composite studies. 4 In all three reviews, the number of studies cited was much lower than the number we found.Abstraction of results and quality assessment for all studies were carried out independently by SE and JH. We have chosen to focus here on the issues of informed consent, doctor-patient relationship, what motivates participants, equipoise, and restricting new treatments to trials. Other issues are summarised elsewhere.1 Quality assessment was difficult in many cases because insufficient information was given by the authorsperhaps itself an indicator of poor quality. The dimensions of methodological rigour used are listed in table 1. Our detailed findings are available in the form of a Health Technology Assessment monograph.1 Here, we discuss the salient findings in narrative style. The results were often surprising and sometimes even shocking.